Evaluating the use of early hormonal therapy in patients with localised or locally advanced prostate cancer

Prostate Cancer and Prostatic Diseases

Volumn 8, Issue 2, 2005, Pages 140-151

  Kaisary, Amir V ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Castration; Hormonal therapy; Luteinising hormone releasing hormone agonist; Nonsteroidal antiandrogen; Prostate cancer

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; CYPROTERONE ACETATE; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; STEROID; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADVANCED CANCER; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CASTRATION; CLINICAL TRIAL; GYNECOMASTIA; HUMAN; LYMPH NODE METASTASIS; MASTALGIA; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; REVIEW; CANCER STAGING; DISEASE COURSE; DRUG ADMINISTRATION; MALE; PATHOLOGY; PROSTATE TUMOR; SURVIVAL; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; CASTRATION; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; NEOPLASM STAGING; ORCHIECTOMY; PROSTATECTOMY; PROSTATIC NEOPLASMS; QUALITY OF LIFE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 23944498180     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500800     Document Type: Review

References (62)

1. Stephenson RA. Prostate cancer trends in the era of prostate-specific antigen. An update of incidence, mortality, and clinical factors from the SEER database. Urol Clin North Am 2002; 29: 173-181.
2. Jemal A et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54: 8-29.
3. Grossfeld GD et al. Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer. J Urol 2003; 169: 157-163.
4. Catton C et al. Clinical and biochemical outcome of conventional dose radiotherapy for localized prostate cancer. Can J Urol 2002; 9: 1444-1452.
5. Gretzer MB et al. Substratification of stage T1c prostate cancer based on the probability of biochemical recurrence. Urology 2002; 60: 1034-1039.
6. Hull GW et al. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002; 167: 528-534.
7. Koppie TM et al. Patterns of treatment of patients with prostate cancer initially managed with surveillance: Results from the CaPSURE database. J Urol 2000; 164: 81-88.
8. Klotz L. Active surveillance with selective delayed intervention: Using natural history to guide treatment in good risk prostate cancer. J Urol 2004; 172: S48-S50.
9. Rosenfeld B et al. Differences in health-related quality of life of prostate cancer patients based on stage of cancer. Psychooncology 2004; 13: 800-807.
10. Lintz K et al. Prostate cancer patients' support and psychological care needs: Survey from a non-surgical oncology clinic. Psychooncology 2003; 12: 769-783.
11. Smith MR. Osteoclast-targeted therapy for prostate cancer. Curr Treat Options Oncol 2004; 5: 367-375.
12. Smith Jr JA, Soloway MS, Young MJ. Complications of advanced prostate cancer. Urology 1999; 54 (Suppl 6A): 8-14.
13. Ullrich PM et al. Cancer fear and mood disturbance after radical prostatectomy: Consequences of biochemical evidence of recurrence. J Urol 2003; 169: 1449-1452.
14. Penson DF et al. The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: Findings from a retrospective analysis of health plan data. J Urol 2004; 171: 2250-2254.
15. Groot MT et al. Costs of prostate cancer, metastatic to the bone, in the Netherlands. Eur Urol 2003; 43: 226-232.
16. Bolla M et al. Does post-operative radiotherapy (P-RXT) after radical prostatectomy (Px) improve progression-free survival (PFS) in pT3N0 prostate cancer (PC)? (EORTC 22911). Proc Am Soc Clin Oncol 2004; 23: 382, 4504.
17. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council trial. Br J Urol 1997; 79: 235-246.
18. Kirk D, on behalf of the Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate vs. deferred hormone treatment for prostate cancer: How safe is androgen deprivation? BJU Int 2000; 86 (Suppl 3): 220, MP6.1.07.
19. Schroder FH et al. Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: Results of European Organisation for the Research and Treatment of Cancer 30846 - a phase III study. J Urol 2004; 172: 923-927.
20. Wirth MP et al. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: Results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J Urol 2004; 172: 1865-1870.
21. Messing E et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node positive prostate cancer: Results at 10 years of EST 3886. J Urol 2003; 169: 396, 1480.
22. Messing EM et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999; 341: 1781-1788.
23. Prayer-Galetti T et al. Disease free survival in patients with pathological 'C STAGE' prostate cancer at radical retropubic prostatectomy submitted to adjuvant hormonal treatment. Eur Urol 2000; 38: 504, 48.
24. Wirth MP et al. Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer. Eur Urol 2004; 45: 267-270.
25. Zincke H et al. Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer. J Urol 2001; 166: 2208-2215.
26. Prezioso D et al. Neoadjuvant hormone treatment with leuprolide acetate depot 3.75mg and cyproterone acetate, before radical prostatectomy: A randomized study. Urol Int 2004; 72: 189-195.
27. Klotz LH et al. Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol 2003; 170: 791-794.
28. Aus G et al. Three-month neoadjuvant hormonal therapy before radical prostatectomy: A 7-year follow-up of a randomized controlled trial. BJU Int 2002; 90: 561-566.
29. Soloway MS et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxM0 prostate cancer: 5-year results. J Urol 2002; 167: 112-116.
30. Schulman CC et al. 4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. Eur Urol 2000; 38: 706-713.
31. Labrie F et al. Neoadjuvant hormonal therapy: The Canadian experience. Urology 1997; 49 (Suppl 3A): 56-64.
32. Bolla M et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 2002; 360: 103-108.
33. Lawton CA et al. Updated results of the Phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 49: 937-946.
34. Pilepich MV et al. Phase III trial of androgen suppression adjuvant to definitive radiotherapy. Long term results of RTOG study 85-31. Oral presentation at the 39th American Society for Clinical Oncology Annual Meeting, 31 May-03 June 2003, Chicago, IL, USA. Available at: http://www.asco.org/ac/1,1003,_12-002511-00_18-0023-00_19-001808,00.asp, accessed 8 March 2005.
35. Hanks GE et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92432. J Clin Oncol 2003; 21: 3972-3978.
36. Granfors T et al. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: A prospective randomized study. J Urol 1998; 159: 2030-2034.
37. D'Amico AV et al. 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA 2004; 292: 821-827.
38. Pilepich MV et al. Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate, Int J Radiat Oncol Biol Phys 2001; 50: 1243-1252.
39. Porter AT et al. A phase III randomized trial to evaluate the efficacy of neoadjuvant therapy prior to curative radiotherapy in locally advanced prostate cancer patients. A Canadian Urologic Oncology Group study. Proc Am Soc Clin Oncol 1997; 16: 315a, 1123.
40. Laverdière J et al. The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer. J Urol 2004; 171: 1137-1140.
41. Oh WK. Secondary hormonal therapies in the treatment of prostate cancer. Urology 2002; 60 (Suppl 3A): 87-93.
42. Wirth M et al. Response to second-line hormonal therapy following progression on bicalutamide ('Casodex') 150mg monotherapy. Eur Urol Suppl 2004; 3: 58, 223.
43. Manne SL. Prostate cancer support and advocacy groups: Their role for patients and family members. Semin Urol Oncol 2002; 20: 45-54.
44. Zietman AL et al. Conservative management of prostate cancer in the prostate specific antigen era: The incidence and time course of subsequent therapy. J Urol 2001; 166: 1702-1706.
45. Critz FA et al. Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer. J Urol 2000; 163: 1085-1089.
46. Green HJ et al. Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: A randomized controlled trial. BJU Int 2004; 93: 975-979.
47. Sculpher M et al. Patients' preferences for the management of non-metastatic prostate cancer: Discrete choice experiment. BMJ 2004; 328: 382.
48. Sieber PR et al. Bicalutamide 150mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. J Urol 2004; 171: 2272-2276.
49. van Andel G, Kurth KH. The impact of androgen deprivation therapy on health related quality of life in asymptomatic men with lymph node positive prostate cancer. Eur Urol 2003; 44: 209-214.
50. Smith MR et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002; 87: 599-603.
51. Daniell HW et al. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000; 163: 181-186.
52. Iversen P et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol 2000; 164: 1579-1582.
53. Strum SB et al. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 1997; 79: 933-941.
54. Iversen P et al. A randomised comparison of bicalutamide ('Casodex') 150mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group study no. 6. Eur Urol 2002; 42: 204-211.
55. Fourcade R-O, McLeod D. Tolerability of antiandrogens in the treatment of prostate cancer. UroOncology 2004; 4: 5-13.
56. Tyrrell CJ et al. Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia. Int J Radiat Oncol Biol Phys 2004; 60: 476-483.
57. Van Poppel H et al. Efficacy and tolerability of radiotherapy as treatment for bicalutamide-induced breast pain and gynaecomastia in prostate cancer. Eur J Cancer 2003; 1 (Suppl 5): S265, 881.
58. Widmark A et al. Does prophylactic breast irradiation prevent antiandrogen-induced gynecomastia? Evaluation of 253 patients in the randomized Scandinavian trial SPCG-7/SFUO-3. Urology 2003; 61: 145-151.
59. Eaton AC, Makris A, Makris A. Once weekly tamoxifen in the prevention of gynaecomastia and breast pain secondary to bicalutamide therapy. J Urol 2004; 171: 282, 1069.
60. Boccardo F et al. Tamoxifen (T) is more effective than anastrozole (A) in preventing gynecomastia induced by bicalutamide (B) monotherapy in prostate cancer (pca) patients (pts). Proc Am Soc Clin Oncol 2003; 22: 400, 1608.
61. Saltzstein D et al. Prophylactic tamoxifen significantly reduces the incidence of bicalutamide-induced gynaecomastia and breast pain. BJU Int 2002; 90 (Suppl 2): 120-121, PD-4.07.
62. Schröder FH et al. Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892. Eur Urol 2004; 45: 457-464.